266 Glutamine promotes antibiotic uptake to kill multidrug-resistant uropathogenic bacteria.

265 An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

264 Rational design of a new antibiotic class for drug-resistant infections.

263 A repurposing screen identifies the orally available drug masitinib as able to inhibit virus replication in mouse-based models of COVID-19.

262 The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.

261 Inhalable nanocatchers for SARS-CoV-2 inhibition.

260 The antibiotic darobactin mimics a β-strand to inhibit outer membrane insertase.

259 Neutralization of endothelial lipase with a monoclonal antibody raises functional HDL in both nonhuman primates and in healthy humans.

258 Neoadjuvant treatment with nivolumab plus ipilimumab is well tolerated and demonstrates clinical efficacy in patients with early stage lung cancer.

257 A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.

256 The clinically approved drugs ticagrelor and oseltamivir fortify a pathway of platelet-mediated immunity to clear staphylococcal bacteremia in mice.

255 Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain.

254 Bepridil is potent against SARS-CoV-2 in vitro.

253 Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.

252 Targeting cartilage EGFR pathway for osteoarthritis treatment

251 Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties.

250 A deltamethrin crystal polymorph for more effective malaria control.

249 Designed miniproteins bind tightly to the SARS-CoV-2 spike protein and prevent binding to the host cell receptor.

248 Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

247 Modular synthesis and structural biology are used to design and characterize group A streptogramin antibiotics, one of which has activity against streptogramin-resistant strains and demonstrates efficacy in a mouse model of bacterial infection.

Free Images for Presentation: sunipix SUNIPIX